Horizon Therapeutics Completes Enrollment In Phase 3 Trials For Lead Product Candidate HZT-501

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, announced that it is closing enrollment in its two phase 3 trials HZ-CA-301 and HZ-CA-303 for its lead product candidate HZT-501, an investigational prescription NSAID (non-steroidal anti-inflammatory drug) designed to be “GI-friendly”. “We enrolled over fifteen hundred patients in less than a year, which was well ahead of our projections,” said George F. Tidmarsh, M.D., Ph.D.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on February 12th, 2008